How to Implement eCOA to Achieve Patient-Centric Clinical Research?
2021In recent years, the Center for Drug Evaluation (CDE) of the National Medical Products Administration has successively issued multiple guidance documents, explicitly encouraging the use of eCOA/ePRO tools in clinical drug trials. This signifies that eCOA is gradually transitioning from its “nascent stage” to a “mature application phase.” At the present stage, regardingFor clinical trial leads at pharmaceutical companies or CROs, the following concerns are common:
"What is the value of eCOA compared to Paper COA?"
"Can eCOA, as source data, be modified?"
To answer these questions，October 1, 2022June 9, 16:0000-17：30，VCBeat SelectPartner with a Leading Domestic Digital Clinical Trial EnterpriseYi Lin Yun，Co-hosted by"How to Apply eCOA to Achieve 'Patient-Centric' Clinical Research?"Online Live Open Course。During the course,Dr. Qin Long, CEO of Yilin CloudAdopting a cutting-edge perspective, this article provides pharmaceutical companies and CROs with a comprehensive overview of all aspects of eCOA.
Moreover, this session also featuresDr. Shen Yifeng, Chief Physician at the Shanghai Mental Health CenterandDr. Tong Guo, Vice President of Business Development, Greater China, IQVIAParticipate Together[The Significance and Value of eCOA in Patient-Centered Clinical Trials]Themed Roundtable Discussion: Helping Pharmaceutical Companies and CROs Identify the Right Methodologies Based on Case Study Experience.
Participants in the live interactive consultationTop 20Audience, Yi Lin Yun also offers a SaaS system (choose one from EDC, RTSM, CTMS, eTMF, eCOA, etc.)3 monthsTrial Benefits. More chances to claim during the live streamCash Red Packets! Scan the QR code in the poster below to register for the live stream:
What is eCOA?
What Is the Attitude of Global Regulatory Authorities Toward eCOA?
The Value of eCOA Compared to Paper COA
Can eCOA, as source data, be modified?
What Kind of eCOA System Meets Regulatory Requirements?
Founders and Partners of Companies with Innovative Clinical Research Projects
[Recommendation: ★★★★★]
Enterprises with innovative clinical research projects, and heads of departments related to clinical trials
[Recommendation: ★★★★]
Enterprises with innovative clinical research projects, and eCOA system administrators in departments related to clinical trials
[Recommendation: ★★★]
If you belong to any of the above groups, be sure not to miss this information-packed open lecture.
Ph.D. in Management from Beihang University; conducted postdoctoral research at Sun Yat-sen University, specializing in medical statistics. Possesses over 16 years of experience in the application of technologies within the clinical research industry. An innovative and inspiring leader, he is a pioneer in promoting and implementing technical solutions such as eCOA, EDC, and CTMS in China’s clinical trial research sector. Previously served as the Head of Asia-Pacific for an international technology company, driving rapid business growth in the region. An entrepreneur who draws motivation from academia and science, he is passionately committed to shaping the future models of clinical trials.
Chief Physician, Director of the Institutional Office, and Ethics Committee Member at the Shanghai Mental Health Center. Served as Deputy Leader of the GCP Platform for Psychotropic Drugs under the National Major Science and Technology Special Project on “Major New Drug Development” from 2008 to 2020, and is also a core member of the China QA Forum.
Dr. Tong Guo | Vice President, Business Development, Greater China, IQVIA
Holds a Master’s and Ph.D. in Biostatistics from McGill University, Canada. Possesses over 20 years of extensive industry experience in biostatistics, clinical operations, and corporate management within both Chinese domestic and global pharmaceutical companies. Has led the statistical design and analysis for multiple global multicenter clinical trials, with profound research expertise in clinical trial design and analysis, real-world studies, healthcare big data, and artificial intelligence applications.
Yi Lin Yun Tech is a healthcare and life sciences enterprise based in China with a global service footprint. Guided by its mission to “leverage technological innovation to deliver effective treatments for patients,” the company is driven by science and medicine. By integrating digital technologies with life science data, it has built a full-process cloud platform for digital clinical trials and provides technical solutions for clinical endpoint assessment. These offerings help pharmaceutical companies and research institutions both in China and abroad improve R&D efficiency and accelerate the market launch of drugs and medical devices, ultimately benefiting countless patients.
“Artery Open Course” is one of the brand columns under VCBeat’s “VCBeat Select.” Focusing on pain points in the medical field and systematic solutions, it leverages an online live-streaming platform for knowledge sharing and exchange. By continuously inviting seasoned industry practitioners and experts to collaboratively develop a series of thematic courses, it aims to provide medical enterprises with in-depth, high-value content. Artery Open Course: Making the selection of knowledge simpler.
Scan the QR code below to contact the assistant and schedule a live broadcast.
